A) Prolixin B) Geodon C) Zyprexa D) Risperdal
A) Invega B) Clozaril C) Abilify D) Zyprexa
A) Abilify B) Zyprexa C) Invega D) Seroquel
A) Seroquel B) Risperdal C) Zyprexa D) Abilify
A) Risperdal B) Geodon C) Abilify D) Seroquel
A) Quetiapine B) Clozapine C) Ziprasidone D) Olanzapine
A) Aripriprazole B) Risperidone C) Ziprasidone D) Paliperidone
A) Seroquel B) Geodon C) Risperdal D) Clozaril
A) Clozapine B) Aripiprazole C) Ziprasidone D) Paliperidone
A) Quetiapine B) Olazapine C) Risperdone D) Paliperidone
A) Aripiprazole and Paliperidone B) Clozapine and Aripiprazole C) Risperidone and Paliperidone D) Clozapine and Risperadone
A) 1-3 B) 2-5 C) 4-5 D) 1
A) 18 B) 12 C) 24 D) 6
A) TRUE B) FALSE
A) Develop more adaptive coping skills B) Foster patients' medication compliance C) Minimize side effects of medication D) Prevent relapse into another psychotic episode
A) one year after discontinuation of medication B) directly after discontinuation of medication C) six months after discontinuation of medication D) several weeks after discontinuation of medication
A) Thorazine B) Symmetrel C) Clozaril D) Artane
A) weight gain more common B) tardive dyskinesia more common C) increased effectiveness for positive, negative, and disorganized symptoms D) enhanced efficacy in treatment-resistant patients
A) Clozapine B) Risperidone C) Haloperiodol D) Prochlorperazine
A) Stimulants B) Alcohol C) Anxiolitics D) Anticonvulsants
A) Halperiodol B) Beta blockers C) Alcohol D) Merperidine
A) Beta blockers B) Nicotine C) Anticonvulsants D) Antacids
A) Tricyclic antidepressants B) Beta blockers C) Alcohol D) SSRIs
A) TRUE B) FALSE
A) Alcohol use B) Tobacco use C) Drug holidays D) Male gender
A) FALSE B) TRUE
A) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. B) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. C) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. D) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia.
A) Akathesia B) Ataxia C) Akinesia D) Acute dystonia
A) Gynecomastia B) Neuroleptic Malignant Syndrome C) Postural hypotension D) Agranulocytosis
A) TRUE B) FALSE
A) TRUE B) FALSE
A) block D2 receptors in the pituitary gland and inhibit prolactin secretion. B) antagonize the normal dopamine-mediated inhibition of prolactin release. C) agonize the normal dopamine-mediated inhibition of prolactin release. D) block D2 receptors in the pituitary gland and decrease prolactin secretion.
A) receptor binding and DA turnover B) hungry hungry hippos C) neuroendocrine changes D) molecular structure
A) Sleepykoaladones B) Butyrophenones C) Phenothiazines D) Thioxanthenenes
A) Potent; low; lower B) Potent; low; higher C) Weak; high; higher D) Weak; high; lower
A) Anhedonia B) Formal thought disorder C) Delusions D) Hallucinations
A) Neurological disorders B) All of the above C) Metabolic disorders D) Autoimmune diseases E) Endocrine disorders
A) All of the above B) Alcohol C) Hallucinogens D) Opioids E) Stimulants
A) FALSE B) TRUE
A) positive symptoms of Schizophrenia. B) disorganized symptoms of Schizophrenia. C) negative symptoms of Schizophrenia. D) All of the above.
A) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake. C) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake. D) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release.
A) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. B) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. C) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine.
A) increased rates of synthesis B) increased release of dopamine C) increased tap dancing D) increased rates of firing
A) thioxanthenes B) piperideines C) aliphatics D) piperazines
A) genecomastia B) menstrual irregularity C) all of the above D) galactorrhea
A) Benadryl (diphenhydramine) B) Cogentin (benztropine) C) Artane (trihexphenidyl) D) Symmetrel (amantadine) E) Inapsine (droperiodol)
A) FALSE B) TRUE
A) polypharmacy B) actual impact at the biological level C) comparative lack of EPS D) superior impact on positive symptoms
A) Haldol B) Clozaril C) Invega D) Abilify
A) Clorazil B) Geodon C) Seroquel D) Risperdal |